PULSE BIOSCIENCES, INC.
Close on Oct 19, 2026
- Market cap
- $3.29B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $400.00K | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 4, 2026 | Before market open | $400.00K | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 19, 2026 | After market close | $264.00K | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | After market close | $86.00K | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | – | $-0.25 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 28, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 15, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | After market close | – | – | – |
Press releases
Announcements Pulse Biosciences filed with the SEC
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
Other events · EX-99.1 to Form 8-K
PULSE BIOSCIENCES, INC. ANNOUNCES PLANNED REDEMPTION OF WARRANTS
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Other events · EX-99.1 to Form 8-K
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse ™ Cardiac Catheter System at Heart Rhythm 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pulse Biosciences Strengthens Executive Leadership Team
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED APRIL 7, 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED MARCH 17, 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED MARCH 12, 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED MARCH 9, 2026
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED FEBRUARY 5, 2026
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED DECEMBER 18, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED DECEMBER 9, 2025
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED OCTOBER 24, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED OCTOBER 10, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED SEPTEMBER 8, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED SEPTEMBER 2, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED AUGUST 26, 2025
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PULSE BIOSCIENCES, INC. ANNOUNCES PLANNED REDEMPTION OF WARRANTS
Other events · EX-99.1 to Form 8-K
Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Other events · EX-99.1 to Form 8-K
Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology
Results of operations · Other events · EX-99.2 to Form 8-K